Cargando…
Adenomatous Polyposis Coli loss controls cell cycle regulators and response to paclitaxel in MDA-MB-157 metaplastic breast cancer cells
Adenomatous Polyposis Coli (APC) is lost in approximately 70% of sporadic breast cancers, with an inclination towards triple negative breast cancer (TNBC). TNBC is treated with traditional chemotherapy, such as paclitaxel (PTX); however, tumors often develop drug resistance. We previously created AP...
Autores principales: | Astarita, Emily M., Maloney, Sara M., Hoover, Camden A., Berkeley, Bronwyn J., VanKlompenberg, Monica K., Nair, T. Murlidharan, Prosperi, Jenifer R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351968/ https://www.ncbi.nlm.nih.gov/pubmed/34370741 http://dx.doi.org/10.1371/journal.pone.0255738 |
Ejemplares similares
-
Effect of Adenomatous Polyposis Coli Loss on Tumorigenic Potential in Pancreatic Ductal Adenocarcinoma
por: Cole, Jennifer M., et al.
Publicado: (2019) -
APC selectively mediates response to chemotherapeutic agents in breast cancer
por: VanKlompenberg, Monica K., et al.
Publicado: (2015) -
Erratum to: APC selectively mediates response to chemotherapeutic agents in breast cancer
por: VanKlompenberg, Monica K., et al.
Publicado: (2016) -
Familial adenomatous polyposis
por: Half, Elizabeth, et al.
Publicado: (2009) -
APC loss in breast cancer leads to doxorubicin resistance via STAT3 activation
por: VanKlompenberg, Monica K., et al.
Publicado: (2017)